# A Study of BGB-11417 in Participants With Myeloid Malignancies

> **NCT04771130** · PHASE1,PHASE2 · RECRUITING · sponsor: **BeiGene** · enrollment: 260 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasm

## Interventions

- **DRUG:** BGB-11417
- **DRUG:** Azacitidine
- **DRUG:** Posaconazole
- **DRUG:** BGB-11417
- **DRUG:** BGB-11417

## Key facts

- **NCT ID:** NCT04771130
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-24
- **Primary completion:** 2028-02-08
- **Final completion:** 2028-02-08
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771130, "A Study of BGB-11417 in Participants With Myeloid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04771130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*